What kind of people are "engines"? Studies show that they are more likely to be psychopaths, sadists, and narcissists.

Published Date: 17 Feb 2023

Online dating has revolutionized dating by creating more opportunities to meet partners than ever before.

Read Full News

Latest News

What the Next Accelerated TMS Trial Should Test, With Jonathan Downar, MD Jonathan Downar, MD, PhD

Downar outlines the randomized trial needed to confirm optimal TMS dosing and addresses a safety ceiling on total pulses.

Q3 2026 Recap: Psychiatry News and Updates

Q3 2026 Recap: Psychiatry News and Updates

5 Psychiatry Headlines You Missed in September 2026

5 Psychiatry Headlines You Missed in September 2026

What The FDA Psychedelic Hearing Means for Psychiatrists

What The FDA Psychedelic Hearing Means for Psychiatrists

TMS for MDD Is Changing Fast. Here's What Psychiatrists Need to Know Andrew Leuchter, MD, Scott A. Wilke, MD, PhD, Linda Carpenter, MD

New accelerated TMS protocols and an FDA-approved at-home device are changing how psychiatrists treat MDD after antidepressant failure.

Emerge Phase 3: DT120 Shows Rapid, Durable Relief in MDD John Sonnenberg, PhD

John Sonnenberg, PhD, reflects on Emerge phase 3 topline data for DT120 in MDD, including MADRS outcomes, remission rates, and what comes next.

Todays Updates

STABLE Trial: Breath-Hold Does Not Improve Robotic Bronchoscopy Yield Roshen Mathew, MD, DAABIP

Roshen Mathew, MD, DAABIP, discusses STABLE, in which diagnostic yield was 86.8% with breath-hold vs 92.2% with conventional ventilation.

Insights on the Updated 2026 AHA/ASA Stroke Rehabilitation Guidelines Louie Pasculli, Talya Fleming, MD, Sara Cuccurullo, MD

Sara Cuccurullo, MD, FAAPMR, and Talya Fleming, MD, FAAPMR, of Hackensack Meridian JFK Johnson Rehabilitation Institute, discuss the updated adult stroke rehabilitation and recovery guidelines and their implications for clinical practice.

Todays Updates

STABLE Trial: Breath-Hold Does Not Improve Robotic Bronchoscopy Yield Roshen Mathew, MD, DAABIP

Roshen Mathew, MD, DAABIP, discusses STABLE, in which diagnostic yield was 86.8% with breath-hold vs 92.2% with conventional ventilation.

Insights on the Updated 2026 AHA/ASA Stroke Rehabilitation Guidelines Louie Pasculli, Talya Fleming, MD, Sara Cuccurullo, MD

Sara Cuccurullo, MD, FAAPMR, and Talya Fleming, MD, FAAPMR, of Hackensack Meridian JFK Johnson Rehabilitation Institute, discuss the updated adult stroke rehabilitation and recovery guidelines and their implications for clinical practice.

Latest News

Downar outlines the randomized trial needed to confirm optimal TMS dosing and addresses a safety ceiling on total pulses.

Q3 2026 Recap: Psychiatry News and Updates

5 Psychiatry Headlines You Missed in September 2026

What The FDA Psychedelic Hearing Means for Psychiatrists

New accelerated TMS protocols and an FDA-approved at-home device are changing how psychiatrists treat MDD after antidepressant failure.

John Sonnenberg, PhD, reflects on Emerge phase 3 topline data for DT120 in MDD, including MADRS outcomes, remission rates, and what comes next.

News All Time

3 Psychiatry Headlines You Missed in July 2026 Chelsie Derman

Centanafadine FDA approval, DT120 EMERGE trial results, and COMP360 psilocybin data headline this month's psychiatry coverage.

FDA Approves Centanafadine for ADHD in Adults, Children Aged ≥ 6 Years Chelsie Derman

The first-in-class NDSRI showed significant symptom improvement as early as week 1 across 4 phase 3 trials but carries boxed warnings for suicidality and abuse potential.

Ketamine, Psychedelics Share Neuroimmune Signature in TRD Chelsie Derman

A biomarker study links immune signaling (IL-7/IL-15) and brain gamma-wave activity to ketamine response in TRD.

Metabolic Traits Differentiate AERS+, AERS− MDD Subtypes, With Arvid Harder Arvid Harder

New genome-wide data show AERS+ and AERS− subtypes of major depressive disorder diverge in heritability and metabolic genetic correlations.

Voyage: DT120 ODT Reduces Anxiety in Phase 3 GAD Trial Chelsie Derman

DT120 ODT produced a 5.4-point placebo-adjusted HAM-A reduction at week 12 in the phase 3 Voyage trial for generalized anxiety disorder.

AERS Subtypes Show Distinct Genetic Architecture in MDD Arvid Harder

A genome-wide study of > 460,000 individuals identify 27 loci separating AERS+ and AERS− subtypes of major depressive disorder by metabolic profile.

MDMA-Assisted Therapy NDA Resubmitted to FDA for PTSD Chelsie Derman

Resilient Pharmaceuticals has resubmitted its MDMA-assisted therapy NDA for PTSD without a new phase 3 trial, MAPS reported.

TMS Sessions Reduced From 38 Minutes to 3, With Jonathan Downar, MD, PhD Jonathan Downar, MD, PhD

Downar says shorter sessions, accelerated schedules, and expanding neuroimaging maps have made TMS effective for more patients in far fewer visits.

Do More TMS Pulses Track with Better Depression Outcomes? Jonathan Downar, MD, PhD

A new meta-analysis found total pulse count predicted outcomes in a roughly linear pattern across sham-controlled trials of accelerated rTMS.

DT120 ODT Receives Second FDA Breakthrough Therapy Designation in MDD Chelsie Derman

The FDA granted DT120 (lysergide) ODT Breakthrough Therapy designation for MDD, citing promising phase 3 Emerge data.

Lower TMS Intensity Correlates With Greater Depression Improvement Chelsie Derman

A randomized TMS trial found lower DLPFC electric-field strength, not higher intensity, correlated with greater depression improvement.

Q&A: Accelerated TMS Speeds Suicidal Ideation Relief, With Owen Muir, MD Owen Muir, MD, DFAACAP, FCTMSS

SWIFT accelerated Deep TMS resolved suicidal ideation faster than standard dosing, Owen Muir, MD, says.

ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD

ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD

Q&A: Woolley on UMBRAA's Multidrug Approach to Psilocybin Trial Masking

Q&A: Woolley on UMBRAA's Multidrug Approach to Psilocybin Trial Masking

Phase 3 PARADIGM: HLP003 (Psilocibin-d10) for Adjunctive MDD Use

Phase 3 PARADIGM: HLP003 (Psilocibin-d10) for Adjunctive MDD Use

Walmart Pasta Recall; 'Ketamine Bladder' in Kids; Panettiere's Cause of Death

Health news and commentary gathered by MedPage Today staff

Recommended News For You

No Survival Benefit Seen With Adjuvant Atezolizumab in TNBC

Study Homes In on Simpler Lung Cancer Screening Criteria

FDA Approves Treosulfan as Part of AML/MDS Conditioning Regimen

Chronic stress and obesity work together to accelerate pancreatic cancer development and growth, study finds

Make the Diagnosis: Can You Explain Her Rash and Conjunctival Injection?

Significant differences in breast cancer care still exist, but surgeons can change.

enhancing survivors of brain tumors' quality of life.

Recommended Articles For You

Cancer Survivorship and Social Reintegration: Clinical Insights and Evidence-Based Approaches 

Early Diagnosis of Lung Cancer Through Emerging Biomarkers 

Voices That Heal: Redefining Cancer Care Through Patient Insights and Partnership 

Hematopoietic Reserve Exhaustion in Chronic Blood Disorders 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Radionuclide-Containing Combo Slows Metastatic Prostate Cancer, Improves Survival

2.

Modified personalized cancer vaccine generates powerful immune response

3.

For the treatment of vestibular schwannomas in neurofibromatosis type 2, stereotactic radiosurgery has been found to be effective.

4.

In a randomized trial, the kinder, gentler regimen for classical Hodgkin wins out.

5.

A smartphone app enhances the tracking of recovery following breast and gynecologic oncology surgery, according to JAMA.

1.

The Future of Oncology: Innovations Every Doctor Should Know

2.

Fatigue Management in Hematologic Disorders

3.

Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study

4.

Guideline Evolution in Benign Hematologic Conditions

5.

The Latest Causes and Symptoms of Bowen's Disease: All You Need to Know 

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III

2.

Predicting Durable Response to Tumor-Directed Radiotherapy Through Clonal Repopulation Dynamics

3.

Virtual Case Study on Deep Vein Thrombosis (DVT) - An Initiative by Hidoc Dr.

4.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V

5.

Advances in Modern Cancer Treatment

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot